Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Technical Committee...

    Technical Committee recommends CDSCO to approve import, marketing of Sanofi TB drug with clinical trial waiver

    Farhat NasimWritten by Farhat Nasim Published On 2019-05-28T16:21:26+05:30  |  Updated On 17 Aug 2021 10:09 AM IST
    New Delhi: Apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has been recommended by the Techincal Committee to granted permission to Sanofi (India) Pvt Ltd to import and market Refapentine film-coated tablet 150mg (PRIFTIN) in the country without conducting a clinical trial of the said formulation.

    The decision comes after detailed deliberation of the recommendation submitted by the Subject Experts Committee (SEC) in this regard. A year ago, the SEC Committee (Antimicrobial & Antiviral) functional under CDSCO examined Sanofi's proposal in its meeting. The firm presented their proposal along with non-clinical & clinical data generated outside India in support of drug for the treatment of latent TB infection with a request for a local clinical trial waiver.

    The committee noted that India aims to eliminate TB by 2025. Treatment of LTBI is an important component for the elimination of TB in India. The Rifapentine is included in the WHO Essential Medicines List. The drug is reported to have an advantage of once weekly regimen for 3 months for treatment of LTBI.

    After careful examination, the committee considered that there is an unmet need of this drug for the treatment of LTBI and recommended that in public interest permission to import & market the drug should be granted with a local clinical trial waiver for the treatment of LTBI. However, the nod for the drug is subject to certain conditions which read;

    • This drug should be available only through the National TB control program in the treatment of LTBI.

    • Phase IV clinical trial shall be conducted by the firm through the programme, for which protocol should be developed in consultation with the programme expert & submitted to CDSCO for review through SEC.


    The matter was referred to Technical Committee for further deliberation, whether based on the justification submitted by the firm and recommendation of SEC permission to manufacture and market Refapentine film-coated tablet 150mg can be given to the firm with a clinical trial waiver.

    The Technical Committee after detailed deliberation agreed with the recommendation of the Subject Expert Committee (Antimicrobial & Antiviral) and recommended for grant of permission to import and market the drug in the country with a local clinical trial waiver subject to the same conditions as recommended by the SEC.

    The drug, Refapentine film-coated tablet is sold under the brand name Priftin and is indicated for the treatment of latent tuberculosis infection caused by Mycobacterium tuberculosis in adults and children 2 years and older who are at high risk of progression to tuberculosis disease (Including those in close contact with active tuberculosis patient, recent conversion to positive tuberculin skin test, HIV infected patients or those with pulmonary fibrosis on radiograph). Refapentine is Active TB should be ruled out before imitating treatment for latent TB infection

    It is reported that the Refapentine( Priftin) was approved by USFDA for LTBI indication in 2014. Later it is also approved in Taiwan, Hongkong and Phillippines.




    Headquartered in Paris, the company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. The company engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication.





    Also Read: Setback: USFDA rejects Sanofi, Lexicon Sotagliflozin for type 1 diabetes
    Active TBAntimicrobialAntiviralCDSCOCentral Drugs Standard Control OrganizationClinical Trialclinical trial waiverHIVHongkongLTBIMycobacterium Tuberculosispaediatric patientPhase IVphillippinesradiographRefapentineRefapentine film coated tabletsSanofiSEC CommitteeTaiwanTBTB control programTB drugtb eliminationtb elimination in IndiaTB infectionTuberculosisUSFDA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok